Mutation distribution in the MUP study group was similar to those observed in other groups with melanoma of known primary site at stage III and IV and included 53 % of BRAF mutants (with the p.V600E as the most prevalent mutation) and 14 % of mutually exclusive NRAS mutants.6,16,18,25–27 No KIT mutations were found. Here, NRAS is linked to melanoma.